# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Amit Dayal maintains Cibus (NASDAQ:CBUS) with a Buy and maintains $25 price target.
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...
Cibus has agreed to collaborate with Loveland Products to provide traits into Loveland's elite rice seed genetics. Under th...
Cibus continues to confirm tolerance of HT1 and HT3 rice traits to commercial herbicide application rates in field trials and...
Breakthrough believed to represent the world's first successful regeneration of a wheat plant from single cells – a major...
-424B5
Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies,...
In the peer reviewed publication, the International Journal of Plant Biology, Cibus provides two case studies of improving olei...